JP2019501224A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501224A5 JP2019501224A5 JP2018554651A JP2018554651A JP2019501224A5 JP 2019501224 A5 JP2019501224 A5 JP 2019501224A5 JP 2018554651 A JP2018554651 A JP 2018554651A JP 2018554651 A JP2018554651 A JP 2018554651A JP 2019501224 A5 JP2019501224 A5 JP 2019501224A5
- Authority
- JP
- Japan
- Prior art keywords
- carboxylic acid
- trifluoromethyl
- chromene
- group
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276713P | 2016-01-08 | 2016-01-08 | |
| US62/276,713 | 2016-01-08 | ||
| US201662277225P | 2016-01-11 | 2016-01-11 | |
| US62/277,225 | 2016-01-11 | ||
| PCT/US2017/012737 WO2017120591A1 (en) | 2016-01-08 | 2017-01-09 | Combination of a chromene compound and a second active agent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501224A JP2019501224A (ja) | 2019-01-17 |
| JP2019501224A5 true JP2019501224A5 (enExample) | 2020-02-13 |
| JP6942726B2 JP6942726B2 (ja) | 2021-09-29 |
Family
ID=59274050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554651A Active JP6942726B2 (ja) | 2016-01-08 | 2017-01-09 | クロメン化合物および第２活性薬剤の併用薬 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20170196835A1 (enExample) |
| EP (1) | EP3400218A4 (enExample) |
| JP (1) | JP6942726B2 (enExample) |
| KR (1) | KR20180100652A (enExample) |
| CN (1) | CN108779091B (enExample) |
| AU (1) | AU2017206108B2 (enExample) |
| MX (1) | MX388579B (enExample) |
| WO (1) | WO2017120591A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017269335B2 (en) | 2016-05-26 | 2021-07-01 | Recurium Ip Holdings, Llc | EGFR inhibitor compounds |
| JP7134417B2 (ja) * | 2017-07-20 | 2022-09-12 | 国立大学法人北海道大学 | Ｐｄ－１／ｐｄ－ｌ１を標的とする阻害薬とｃｏｘ－２阻害薬との併用 |
| NZ749727A (en) | 2018-01-05 | 2020-07-31 | Gnt Biotech & Medicals Corp | A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy |
| TWI869398B (zh) * | 2019-05-10 | 2025-01-11 | 英商拜西克爾德有限公司 | 治療癌症之方法 |
| JP2022553421A (ja) * | 2019-10-28 | 2022-12-22 | エンジーケム ライフサイエンシーズ コーポレーション | がんの処置のための方法および組成物 |
| CN115135385B (zh) | 2019-11-12 | 2024-05-10 | 纳米医疗有限公司 | 用于治疗癌症的含有ido拮抗剂前药的调配的和/或共同调配的脂质体组合物及其方法 |
| IL297625B2 (en) | 2020-04-29 | 2026-05-01 | Relay Therapeutics Inc | PI3K-alpha inhibitors and methods of using them |
| CA3232906A1 (en) * | 2021-10-07 | 2023-04-13 | Alessandro Boezio | Pi3k-alpha inhibitors and methods of use thereof |
| KR102889598B1 (ko) * | 2023-02-16 | 2025-11-21 | 주식회사 재인알앤피 | 신규한 데커신 유도체, 및 이의 비소세포폐암 예방 또는 치료 용도 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6034256A (en) | 1997-04-21 | 2000-03-07 | G.D. Searle & Co. | Substituted benzopyran derivatives for the treatment of inflammation |
| US20040127470A1 (en) | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
| US20020103141A1 (en) | 1998-12-23 | 2002-08-01 | Mckearn John P. | Antiangiogenic combination therapy for the treatment of cancer |
| AR038957A1 (es) | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
| EP2175722A4 (en) | 2007-07-12 | 2010-08-25 | Tragara Pharmaceuticals Inc | PATIENT SELECTION AND THERAPEUTIC PROCEDURES WITH PROSTAGLAND INMETABOLISM MARKERS |
| CN102757417B (zh) * | 2012-06-18 | 2014-09-24 | 中国科学院广州生物医药与健康研究院 | 氘代苯并吡喃类化合物及其应用 |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| CN103044477B (zh) | 2012-12-07 | 2015-08-05 | 中国科学院广州生物医药与健康研究院 | 三甲基硅取代苯并吡喃类化合物及其应用 |
| CN103012350B (zh) * | 2012-12-07 | 2015-02-04 | 中国科学院广州生物医药与健康研究院 | 苯并吡喃类手性化合物的合成方法 |
| US9452228B2 (en) * | 2013-04-01 | 2016-09-27 | Immunomedics, Inc. | Antibodies reactive with an epitope located in the N-terminal region of MUC5AC comprising cysteine-rich subdomain 2 (Cys2) |
| CA2899577C (en) * | 2013-04-03 | 2023-10-17 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| US20160312297A1 (en) | 2013-12-17 | 2016-10-27 | Merck Sharp & Dohme Corp. | Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists |
| CA2935423C (en) | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| US11034757B2 (en) | 2014-06-09 | 2021-06-15 | Biomed Valley Discoveries, Inc. | Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature |
-
2017
- 2017-01-09 MX MX2018008433A patent/MX388579B/es unknown
- 2017-01-09 WO PCT/US2017/012737 patent/WO2017120591A1/en not_active Ceased
- 2017-01-09 KR KR1020187022783A patent/KR20180100652A/ko not_active Ceased
- 2017-01-09 US US15/401,777 patent/US20170196835A1/en not_active Abandoned
- 2017-01-09 CN CN201780012465.0A patent/CN108779091B/zh active Active
- 2017-01-09 EP EP17736519.4A patent/EP3400218A4/en not_active Withdrawn
- 2017-01-09 AU AU2017206108A patent/AU2017206108B2/en active Active
- 2017-01-09 JP JP2018554651A patent/JP6942726B2/ja active Active
-
2022
- 2022-05-13 US US17/744,185 patent/US12544356B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4356973A3 (en) | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer | |
| SA520411982B1 (ar) | Kirsten 2 مثبطات نظير الجين الورمي الفيروسي لساركوما جرذ (KRas) واستخدامها لعلاج السرطان | |
| JP2016518437A5 (enExample) | ||
| SG11201907038WA (en) | Quinazoline compound | |
| JP2015500887A5 (enExample) | ||
| MY207716A (en) | Hiv inhibitor compounds | |
| JP2017105793A5 (enExample) | ||
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| WO2019035914A8 (en) | Macrocyclic mcl-1 inhibitors and methods of use | |
| MX379459B (es) | Inhibidores de bromodominios. | |
| JP2013542261A5 (enExample) | ||
| JP2016528301A5 (enExample) | ||
| MX2020001717A (es) | Inhibidores macrociclicos de mcl-1 y metodos de uso. | |
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| EP4596048A3 (en) | Cd73 inhibitors | |
| PH12015501836A1 (en) | 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors | |
| JP2019519533A5 (enExample) | ||
| MX2023009388A (es) | Metodos para tratar alteraciones del comportamiento. | |
| JP2016514727A5 (enExample) | ||
| JP2019531356A5 (enExample) | ||
| EA035519B9 (ru) | 1,3,4-тиадиазольные соединения и их применение в лечении рака | |
| HK1255438A1 (zh) | 用於治疗癌症的(s，e)-3-(6-氨基吡啶-3-基)-n-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺 | |
| JP2017515899A5 (enExample) | ||
| EP4591940A3 (en) | Deoxy- cytidine derivatives for use in cancer therapies | |
| AU2018276273A1 (en) | Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer |